公开(公告)号：EP1654238A1

公开(公告)日：2006-05-10

申请号：EP04778640.5

申请日：2004-07-15

申请人： AMGEN INC.

发明人： BUCHANAN, John, L. ,  ELBAUM, Daniel ,  MARTIN, Matthew, W. ,  MCGOWAN, David, C. ,  NOVAK, Perry, M. ,  NUNES, Joseph, J.

IPC分类号： C07D239/48 ,  C07D403/12 ,  C07D401/12 ,  C07D405/12 ,  C07D213/75 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  A61K31/505 ,  A61P37/00

CPC分类号： C04B35/632 ,  C07D213/75 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

摘要： The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula (1) and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.